Medical & affiliate disclosure: CTX Stat provides educational laboratory information and is not a substitute for professional medical advice, diagnosis, or treatment. CTX Stat may receive compensation from some outbound provider links when an affiliate program is active; provider comparisons and rankings are based on consumer fit, effective cost, access, policies, and reputation—not commission.
Quick take: Hereditary cancer genetic testing looks for inherited DNA changes that can raise a person’s lifetime risk for certain cancers. It can be powerful when the right person is tested for the right reason, but it is not a general “cancer check,” it does not diagnose most existing cancers, and a negative result does not always mean average risk. Before ordering a panel, clarify whether you need clinical testing, genetic counseling, insurance billing or self-pay pricing, and a plan for interpreting positive, negative, and uncertain results.
What hereditary cancer genetic testing is
Hereditary cancer genetic testing is a clinical DNA test that looks for inherited, or germline, variants in genes associated with increased cancer risk. These variants are present from birth and can be passed from parent to child. Testing is usually done with a blood sample, saliva sample, or cheek swab, and the laboratory analyzes selected genes for changes that are known, suspected, or unlikely to affect health.
This is different from tumor genomic testing or cancer biomarker testing. Tumor testing studies changes in cancer cells and may help guide treatment, but a tumor result does not automatically prove that a variant is inherited. The National Cancer Institute distinguishes inherited cancer-risk testing from tumor testing and notes that multigene panels are commonly used when no specific familial variant is already known.
Hereditary cancer panels often include genes such as BRCA1, BRCA2, the Lynch syndrome genes MLH1, MSH2, MSH6, PMS2, and EPCAM, and other genes associated with breast, ovarian, pancreatic, prostate, colorectal, endometrial, gastric, melanoma, endocrine, kidney, or other cancer risks. Some panels are focused on one cancer group, while others include dozens of genes across many syndromes.
A useful way to think about testing is this: the test does not tell you whether you will or will not get cancer. It tells you whether the lab found a reportable inherited variant in the genes tested that may change your cancer-risk management or clarify risk for relatives.
Who should consider hereditary cancer genetic testing?
Testing is most useful when your personal or family history suggests a higher chance of an inherited cancer syndrome. The CDC says genetic counseling and testing for hereditary breast and ovarian cancer may be recommended based on personal cancer history, family cancer history, ancestry, or a known familial mutation. The U.S. Preventive Services Task Force recommends BRCA-related risk assessment for women with personal or family histories of breast, ovarian, tubal, or peritoneal cancer, or ancestry associated with BRCA1/2 variants, followed by counseling and testing when indicated.
Common reasons to discuss hereditary cancer genetic testing include:
- Cancer diagnosed at an unusually young age, often before age 50, depending on cancer type.
- Multiple close relatives with the same or related cancers, especially across generations.
- Ovarian, fallopian tube, or primary peritoneal cancer at any age.
- Male breast cancer.
- Pancreatic cancer, metastatic prostate cancer, or high-risk prostate cancer in the family.
- Colorectal or endometrial cancer with abnormal tumor screening suggestive of Lynch syndrome.
- Multiple primary cancers in one person, such as bilateral breast cancers or breast plus pancreatic cancer.
- A known pathogenic or likely pathogenic variant in a blood relative.
- Ashkenazi Jewish ancestry or another ancestry group with known founder variants, especially when paired with relevant personal or family history.
Whenever possible, the most informative first person to test is a relative who has had the cancer of concern. If that person has a pathogenic variant, unaffected relatives can then have targeted testing for the same variant. Testing an unaffected person first can still be appropriate, but a negative result may be less conclusive if no affected relative has been tested.
Lynch syndrome is a good example of why the testing question matters. The CDC notes that genetic testing may be recommended based on personal or family history, a known familial Lynch syndrome mutation, or abnormal tumor testing after colorectal or uterine cancer. If a tumor test suggests Lynch syndrome, a separate germline test is usually needed to determine whether the variant is inherited.
Panel types: single gene, focused panel, broad panel, or direct-to-consumer test?
There is no single “best” hereditary cancer panel for everyone. The right test depends on what question you and your clinician are trying to answer.
| Testing approach | When it may fit | Main limitation |
|---|---|---|
| Targeted familial-variant test | A blood relative has a known pathogenic or likely pathogenic variant | It answers only whether you inherited that specific variant |
| Single-gene test | One syndrome is strongly suspected and the gene is clear | May miss other relevant genes if the family pattern is broader |
| Focused multigene panel | Several genes are relevant to one cancer group, such as breast/ovarian or colorectal/endometrial cancers | Can still produce uncertain results and may not include genes outside that cancer group |
| Broad hereditary cancer panel | Personal or family history could fit more than one syndrome, or a clinician wants a comprehensive germline assessment | Higher chance of variants of uncertain significance and unexpected findings |
| Direct-to-consumer genetic health test | Consumer screening or ancestry-linked variant checks | Often checks selected variants rather than full clinical gene analysis; confirmatory clinical testing may be needed |
Professional guidance increasingly supports multigene panel testing when more than one gene is relevant. For patients with cancer who meet criteria for germline testing, an ASCO guideline on germline panel selection states that multigene panel testing should be offered when more than one gene is relevant based on the person’s cancer history, family history, or other factors. That does not mean the largest possible panel is always best. It means the panel should match the clinical scenario.
Direct-to-consumer tests require special caution. The FDA explains that some genetic health risk tests do not report all variants that may contribute to disease risk. The NCI also notes that, as of its fact sheet update, the FDA-authorized direct-to-consumer BRCA test evaluated only three BRCA founder variants common in people of Ashkenazi Jewish descent, not all BRCA1/2 variants. A negative result on that kind of limited test should not be treated as a full clinical BRCA or hereditary cancer panel.
How hereditary cancer panel results are interpreted
Clinical labs usually classify variants into categories such as pathogenic, likely pathogenic, variant of uncertain significance, likely benign, and benign. These categories are based on evidence frameworks used in medical genetics. The ACMG/AMP sequence-variant standards state that a variant of uncertain significance should not be used in clinical decision-making, while pathogenic and likely pathogenic variants can be clinically actionable when interpreted with the person’s history.
Positive: pathogenic or likely pathogenic variant
A positive result means the lab found an inherited variant known or strongly expected to increase risk for one or more cancers. The next step is not panic; it is risk management. Depending on the gene, options may include earlier or more frequent screening, breast MRI, colonoscopy at shorter intervals, risk-reducing medication, risk-reducing surgery, lifestyle counseling, or testing of relatives. The appropriate plan depends on the gene, the exact variant, sex assigned at birth, age, family history, and personal preferences.
Some positive results also affect cancer treatment. For example, inherited BRCA1/2 variants may influence therapy decisions for certain breast, ovarian, pancreatic, or prostate cancers. However, treatment decisions require oncology interpretation; a hereditary panel result should not be used in isolation.
Negative: no reportable harmful variant found
A negative result can be reassuring, but it is not always definitive. If your family has a known pathogenic variant and you test negative for that exact variant, the result is often considered a true negative for that familial risk. In contrast, if no affected relative has been tested, a negative result may be “uninformative.” Your family history may still justify earlier screening or specialist evaluation.
The MedlinePlus Genetics explanation of genetic test results emphasizes that a negative result means the test did not find the change it was designed to detect; it does not necessarily rule out a genetic condition in every circumstance.
Variant of uncertain significance: a “do not act on this alone” result
A variant of uncertain significance, often shortened to VUS, means the lab found a DNA change but there is not enough evidence to classify it as harmful or benign. A VUS is common enough that every person considering a panel should know about it beforehand. Larger panels tend to increase the chance of uncertain findings simply because more genes are being examined.
Most VUS findings should not change screening or surgical decisions. Instead, your care team generally bases management on your personal and family history while the lab and scientific community continue to gather evidence. Over time, some VUS results are reclassified, often to likely benign or benign. Ask the testing lab or ordering clinician how you will be notified if a result is reclassified.
Cost, insurance, and privacy questions to ask
The out-of-pocket cost of hereditary cancer genetic testing can range from little or nothing to several thousand dollars, depending on insurance coverage, medical necessity criteria, deductible status, ordering pathway, and whether counseling or clinic visits are billed separately. The American Cancer Society notes that many insurance plans cover genetic counseling and testing when considered medically necessary.
Cash-pay options have become more common, but the advertised test price may not be the total cost. For example, some laboratories and programs publicly describe self-pay hereditary cancer panel prices in the low hundreds of dollars, while insurance-billed amounts and patient responsibility can differ. Labcorp’s Invitae program has publicly listed a patient-pay price for an Invitae Cancer Genetic Risk Panel, and Myriad describes insurance coverage, cost estimates, financial assistance, and direct-pay options for hereditary cancer testing. These examples illustrate why consumers should ask for the effective total cost, not just the headline test price.
| Cost item | Question to ask before ordering |
|---|---|
| Genetic test | What is the cash-pay price, and what is my estimated insurance out-of-pocket cost? |
| Ordering clinician or telehealth visit | Is there a separate visit fee to approve or order the test? |
| Genetic counseling | Is pre-test and post-test counseling included, optional, or billed separately? |
| Sample collection and shipping | Are blood draw, saliva kit, return shipping, or collection-network fees included? |
| Follow-up testing | If a relative needs targeted testing, what will that cost? |
| Insurance billing | Will I receive an estimate before the lab starts, and can I switch to self-pay if insurance is expensive? |
Privacy is another practical issue. In the United States, the Genetic Information Nondiscrimination Act, or GINA, generally protects against genetic discrimination in health insurance and employment. However, the U.S. Department of Health and Human Services explains that GINA’s protections do not extend to life insurance, disability insurance, or long-term care insurance. If those policies matter to you, consider discussing timing and implications with a genetics professional before testing.
What to do before ordering a hereditary cancer panel
Preparation can make the difference between a useful result and a confusing one. Start by writing down cancers on both sides of your family, including the type of cancer, age at diagnosis, whether the person is living, and whether any genetic testing has already been done. Include first-degree relatives, such as parents, siblings, and children; second-degree relatives, such as grandparents, aunts, uncles, nieces, nephews, and half-siblings; and any known ancestry relevant to founder variants.
Next, clarify your goal. Are you trying to explain a personal cancer diagnosis? Decide whether you need earlier screening? Learn whether children or siblings need targeted testing? Follow up on a tumor test? Confirm a direct-to-consumer result? Each goal can point to a different test strategy.
Genetic counseling is strongly recommended before and after testing, especially for broad panels. A genetic counselor or genetics-trained clinician can help you understand the most informative person to test, the right panel size, the possibility of uncertain results, what a negative result would and would not mean, and how results may affect relatives. The NCCN Guidelines for Patients on genetic testing for hereditary cancers are a helpful patient-level resource for understanding the testing process and results-based care.
- The exact test name and genes included.
- Whether the lab is performing full gene sequencing, deletion/duplication analysis, targeted founder-variant testing, or another method.
- Your estimated total cost, including required visits and counseling.
- How results will be delivered and who will explain them.
- Whether relatives can receive targeted testing if a pathogenic variant is found.
What happens after results come back?
If your result is positive, ask for a written management plan or referral to the appropriate specialist. Depending on the gene, that may mean a high-risk breast clinic, gastroenterologist, gynecologic oncologist, urologist, pancreatic surveillance program, dermatologist, endocrinologist, or cancer genetics clinic. Also ask for a family letter that explains the variant in plain language so relatives can share it with their own clinicians.
If your result is negative, do not stop recommended screening without checking whether your family history still places you in a higher-risk category. A negative hereditary panel does not erase a strong family history, and it does not replace routine cancer screening such as mammography, colonoscopy, cervical cancer screening, or lung cancer screening when otherwise indicated.
If your result is a VUS, avoid irreversible decisions based on that variant alone. Keep a copy of the report, follow screening recommendations based on your personal and family risk, and ask how reclassification updates are handled.
FAQs
Does hereditary cancer genetic testing tell me whether I have cancer?
No. Germline testing looks for inherited risk variants; it is not a test for an existing cancer in most circumstances. If you have symptoms or an abnormal screening test, you need diagnostic evaluation, not only inherited-risk testing.
Is BRCA testing the same as a hereditary cancer panel?
Not necessarily. BRCA testing focuses on BRCA1 and BRCA2. A hereditary cancer panel may include BRCA1/2 plus many other genes, such as Lynch syndrome genes and genes associated with pancreatic, prostate, breast, ovarian, colorectal, endometrial, gastric, melanoma, or endocrine cancer risks.
Should I test if my relative tested positive?
If a blood relative has a pathogenic or likely pathogenic variant, targeted familial-variant testing is often the clearest next step. Bring a copy of your relative’s report if available, because the exact gene and variant matter.
Can men benefit from hereditary cancer genetic testing?
Yes. Hereditary cancer syndromes can affect people of any sex. BRCA2, for example, can be relevant to male breast, prostate, pancreatic, and melanoma risk, and Lynch syndrome can increase colorectal and other cancer risks. Men can also pass inherited variants to children.
Can children be tested for adult hereditary cancer syndromes?
Usually, testing minors for adult-onset cancer risk is deferred unless results would change medical care during childhood. Some hereditary cancer syndromes do affect childhood management, so this question should be handled with a genetics professional.
What if I already used an at-home DNA test?
Do not assume an at-home result is complete or clinically confirmed. If it reports a concerning variant, ask a clinician or genetic counselor whether confirmatory testing in a clinical laboratory is needed. If it is negative, remember that many consumer tests check selected variants rather than fully analyzing all relevant genes.
How often should results be updated?
Your DNA does not change, but scientific interpretation can. Recontact the ordering clinic or lab if your family history changes, a relative receives a new genetic result, or you previously had limited testing many years ago. Older single-gene tests may not include genes or methods used in current panels.
Sources
- National Cancer Institute: Genetic Testing Fact Sheet
- CDC: Genetic Testing for Hereditary Breast and Ovarian Cancer
- CDC: Genetic Testing for Lynch Syndrome
- USPSTF: BRCA-Related Cancer Risk Assessment, Genetic Counseling, and Genetic Testing
- ASCO: Selection of Germline Genetic Testing Panels in Patients With Cancer
- MedlinePlus Genetics: What Genetic Test Results Mean
- ACMG/AMP: Standards and Guidelines for the Interpretation of Sequence Variants
- HHS: Genetic Information Nondiscrimination Act Guidance
